Small molecule (PROTAC degrader) · Degrader of Androgen receptor (AR) · developed by Novartis Pharmaceuticals
Luxdegalutamide is an orally bioavailable PROTAC protein degrader that links an androgen receptor ligand to an E3 ligase recruiter. It binds the androgen receptor ligand-binding domain, recruits E3 ligase to tag the receptor with ubiquitin, and promotes its proteasomal degradation. It is being studied in castration-resistant prostate cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06991556 | Phase 2 | Metastatic Hormone-sensitive Prostate Cancer | Active not recruiting | NVS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Prostatic Cancer, Castration-Resistant
Updated Nov 15, 2026. Something wrong or missing? Report it on the NVS page.
See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVS catalysts and pipeline →